Applications of single-cell sequencing in cancer research: progress and perspectives

Yalan Lei1,2,3,4†, Rong Tang1,2,3,4†, Jin Xu1,2,3,4†, Wei Wang1,2,3,4, Bo Zhang1,2,3,4, Jiang Liu1,2,3,4, Xianjun Yu1,2,3,4* and Si Shi1,2,3,4*

Abstract
Single-cell sequencing, including genomics, transcriptomics, epigenomics, proteomics and metabolomics sequencing, is a powerful tool to decipher the cellular and molecular landscape at a single-cell resolution, unlike bulk sequencing, which provides averaged data. The use of single-cell sequencing in cancer research has revolutionized our understanding of the biological characteristics and dynamics within cancer lesions. In this review, we summarize emerging single-cell sequencing technologies and recent cancer research progress obtained by single-cell sequencing, including information related to the landscapes of malignant cells and immune cells, tumor heterogeneity, circulating tumor cells and the underlying mechanisms of tumor biological behaviors. Overall, the prospects of single-cell sequencing in facilitating diagnosis, targeted therapy and prognostic prediction among a spectrum of tumors are bright. In the near future, advances in single-cell sequencing will undoubtedly improve our understanding of the biological characteristics of tumors and highlight potential precise therapeutic targets for patients.

Keywords: Single-cell sequencing, Heterogeneity, Microenvironment, Circulating tumor cells

Background
Single-cell sequencing, based on next-generation sequencing, has progressed rapid in recent years. The first single-cell mRNA sequencing experiment was conducted in 2009, the first single-cell DNA sequencing experiment in human cancer cells was conducted in 2011, and the first single-cell exome sequencing experiment was conducted in 2012 [1, 2]. Single-cell sequencing significantly outperforms previous sequencing technologies in terms of our understanding of the human biology of embryonic cells, intracranial neurons, malignant tumor cells and immune cells because it can probe cellular and microenvironmental heterogeneity at single-cell resolution. It has revolutionized our ability to interrogate the transcriptional, genomic, epigenetic and metabolic characteristics of thousands of individual cells in depth, thereby enabling an unbiased analysis of the cells within tumor lesions. It also provides molecular insights, including single-nucleotide variations (SNVs), copy number variations (CNVs) and structural variations (SVs) [3, 4]. However, the limitations of single-cell sequencing should not be neglected; these include its limited sensitivity, scale and accuracy; insufficiency in reconstructing clonal evolution in spatial and temporal order; and noise due to the preamplification of single-cell RNA. These limitations have mainly been overcome by improving the technology itself and combining it with other emerging technologies, enabling researchers to analyze multiomic information at a single-cell resolution.

Single-cell sequencing offers the ultimate resolution, thereby contributing to exploring effective management and personalized therapeutics in a tremendous number of scenarios, such as developmental research, the preparation of human cell atlases and cancer research [5, 6]. In addition to developmental biology, single-cell RNA
sequencing (scRNA-seq) and its derived technologies might assist in the identification of novel markers, rare subgroups and evolution patterns, especially in brain development [7, 8]. In cancer research, it can be used to identify or interrogate (1) rare subpopulations; (2) circulating tumor cells (CTCs); (3) the tumor or immune microenvironment; (4) tumor heterogeneity and molecular subtype; (5) mechanisms associated with tumorigenesis, progression, metastasis, evolution, relapse and therapy resistance; and (6) cancer stem cells (CSCs) [9–12].

In this review, we summarize recent progress in single-cell sequencing technologies, including emerging single-cell sequencing technologies, single-cell sequencing data analysis, and applications in cancer research.

**Emerging single-cell sequencing technologies**

Breakthroughs in single-cell isolation, sequencing, cDNA library preparation and analytical algorithms have led to rapid progress in single-cell sequencing analysis capacity. Single-cell transcriptomics, genomics, proteomics, epigenomics and interactomics sequencing have developed rapidly in recent years.

scRNA-seq technologies share common procedures, including (1) the isolation of a single cell, (2) RNA extraction, (3) reverse transcription, (4) preamplification and (5) detection [13]. The earliest procedures are clearly the most crucial, as they determine the accuracy and amount of the amplified material. A study showed that a lower single-cell dissociation temperature (6 °C) minimizes the stress responses induced at 37 °C, which includes the induction of 512 heat shock proteins. Moreover, the method of dissociation also affects transcription signatures [14].

In addition to the need for single-cell isolation, the greatest challenge in single-cell sequencing is recognizing the sequencing results at the single-cell level. Single-cell barcoding technologies based on plate microreaction systems and combinational indices have completely resolved this bottleneck, thus increasing the throughput of single-cell analysis by at least 100-fold. First, plate microreaction systems usually include single cells, functional beads and reverse transcriptomes. The surface of the functional beads is modified with oligonucleotides, including primers, cell barcodes, unique molecular identifiers (UMIs) and poly(dT) moieties from 5′ to 3′. The primer and poly(dT) moieties are uniform among the microreaction systems, while the cell barcode is unique for each microreaction system, and the UMI is unique for each molecule within a single cell. In addition, the UMI can label various molecules, such as the DNA genome, transcriptome, immune profile and proteome, based on different sequencing purposes. These features guarantee the precise identification of molecular features of a single cell. Drop-seq, Seq-Well and inDrop are bead-based technologies. Zhang et al. revealed the differences between Drop-seq and inDrop in detail. For example, the length of the cell barcode is 38–41 bp in inDrop and 12 bp in Drop-seq, and the cell barcode capacity is 147,456 (384*384) in inDrop and 16,777,216 (412) in Drop-seq [15]. Additionally, the same type of bead is used in Seq-Well and Drop-seq [16]. Another single-cell barcoding technology based on combinational indexing overcomes the limitations of the relatively high cost of isolating a single cell for bead-based barcoding technologies. Combinational indexing-based barcoding technologies recognize single cells by the addition of cellular barcodes in multiple rounds without isolating single cells; these technologies include Sci-Seq, Microwell-Seq and Split-Seq [17]. In Sci-Seq, two rounds of transposase barcoding and PCR ligation labeled 9216 (96*96) single cells. Three split-pool rounds introduced 3 parts of the oligonucleotide sequence to the magnetic beads in Microwell-Seq [18]. However, too few cells for massive analysis are isolated in Sci-Seq and Microwell-Seq. Split-seq, which is based on Sci-Seq, utilizes 5 rounds of barcoding, which significantly improves sequencing over millions of single cells and lowers the cost [8].

After barcode-targeted molecules, the next important procedure is preamplification, in which the transcripts undergo reverse transcription. The preamplification procedure in 10X Genomics technology occurs as follows. First, the transcripts are bound to the 5′ poly(dT) in oligonucleotides by the polyA tail at its 3′ end. Second, the oligonucleotides undergo reverse transcription from the 5′ end to the 3′ end, with the binding transcript used as a template. The oligonucleotide chain extension ends with several C bases whose addition is catalyzed by a special terminal transferase. Third, the template switch oligo (TSO) is added to the template by reverse transcriptase, followed by the addition of the TSO to the other chain. Then, the new full-length cDNA, which is also known as the first-strand cDNA, becomes the new template for cDNA amplification, called the template switch. Fourth, the second cDNA chain is synthesized with the first cDNA chain used as a template [19]. The whole process is called in vitro transcription. In addition, multiple displacement amplification (MDA) is a non-PCR-type DNA amplification method that relies on isothermal amplification. MDA utilizes a special DNA polymerase named bacteriophage phi29 DNA polymerase, which can amplify very small amounts of DNA even from a single cell with a high binding capacity [20]. In addition, newly developed in situ 10-cell RNA sequencing, which utilizes Taq and Phusion polymerases, has dramatically increased the yield of ~500 bp preamplification products.
and enables a tenfold decrease in the T24-containing primer concentration without a detectable loss in pre-amplification efficiency. In addition, in situ 10-cell RNA sequencing allows the simultaneous sequencing of 10 microdissected cells in their normal tissue context [21].

For detection, most single-cell sequencing techniques rely on empirical parameters or predefined structures to estimate the degree of complexity. Recent research revealed that the combination of nonnegative matrix factorization and Bayesian model comparison with current algorithms enables unambiguous assessments of the depth of heterogeneity in the tumor microenvironment (TME) [22]. Single-cell hierarchical Poisson factorization can be used to discover both continuous and discrete expression patterns from de novo scRNA-seq data [23]; moreover, newly developed super CT can train the expandable supervised classifier once the RNA data are input [24]. The accurate interrogation of cell subsets contributes to a better understanding of the clonal composition and heterogeneity.

Moreover, we have summarized the most important single-cell sequencing technologies and platforms in Table 1 [25].

Transcriptomics

Currently, scRNA-seq is widely applied to profile the transcriptomes of individual cells. Droplet-based 10X Genomics Chromium and plate-based Switching Mechanism at the 5′ End of RNA Template sequencing (SMART-Seq) are two frequently used platforms.

The 10X Genomics platform, which is based on a microfluidics approach, is capable of isolating, labeling, amplifying and preparing a cDNA library from 5000 to 10,000 single cells at a high speed. However, it detects only the 3′ or 5′ end of the transcript with a bias, and abundant cells in a single sample (recommended over 90%) are needed. Moreover, the cell capture rate is lower than that of SMART-Seq, so it is not suitable for detecting rare samples containing few cells.

SMART-Seq, which was reported in 2012, facilitates the detection of full-length transcripts [26]. SMART-Seq v2, which was reported in 2013, eliminates purification procedures, replaces the last guanosine at the TSO 3′ end with locked nucleic acid (LNA) and utilizes betaine to increase protein thermal stability, thus significantly increasing the yield [27]. Interestingly, the fundamental basis for full-length sequencing is Moloney murine leukemia virus (MLV) reverse transcriptase, which prefers to use full-length cDNAs as substrates for its terminal transferase. Moreover, SMART-Seq v4 is more efficient in template switching, which shortens the time of cDNA synthesis and cDNA library construction, and has a higher sensitivity for low input and higher reproducibility [28]. SMART-Seq v2 and v4 are widely utilized in cancer research, such as research on hepatocellular carcinoma (HCC) [29–31]. In addition, SMART-Seq does not require additional equipment, which means that it largely depends on experienced researchers.

A recent study compared sequencing data from CD45 cell samples generated by the 10X Genomics and SMART-Seq v2 platforms. In particular, SMART-Seq v2 was more sensitive and detected more genes within a single cell, especially low-abundance transcripts and alternatively spliced transcripts. The use of 10X Genomics increased dropout and showed increased noise in transcripts with low expression. However, 10X Genomics detected more genes due to its superior coverage of abundant cells, which thus enabled the identification of rare cell types. Further analysis of the sequencing data revealed that the two platforms detected distinct differentially expressed genes (DEGs) between cell clusters, indicating the potential to combine complementary results to interrogate heterogeneity [32]. Another study combining 10X Genomics and SMART-Seq v2 revealed the immune cell landscape and analyzed dynamic migration and status switch features in HCC [33].

Spatial transcriptomes and temporal lineage tracing facilitate multifaceted interrogation of the local environment and dynamic interactions within a single cell. Temporal and spatial variability influence tumor heterogeneity and stress reactions and are thus indispensable for cancer diagnosis, subtyping, classification and treatment in cancer research [34–36]. The sequential attachment of spatial barcodes makes it possible to encode and obtain location information on single cells, which can effectively provide information for use in research and diagnosis. For example, a recent study deciphered a detailed spatial map of single-cell phenotypes and cellular communities, which demonstrated phenotypic heterogeneity in the breast TME [37]. Furthermore, single-molecule RNA fluorescence in situ hybridization (smFISH) provides precise spatial information in pancreatic cancer and breast cancer [38, 39].

Cancer progression is a dynamic process that involves several different steps from oncogenesis and metastasis to the development of treatment resistance. Defining the temporal and molecular nature of each step in this process is critical to understanding cancer biology and designing effective treatment strategies. The newly developed technique lineage tracing by nuclease-activated editing of ubiquitous sequences (LINNAEUS) was used to reconstruct lineage trees in zebrafish with great success [40]. Single-cell analysis based on CRISPR-Cas9 technology was used to draw a detailed malignant cell spectrum in a KRAS mutant mouse model. This technique overcomes the difficulty of low mutation sensitivity, as well
| Measurement | Technology | Platform                  | Year | Single cell isolation | Gene coverage | Barcode addition | Library amplification | Reaction volume | Throughput | References |
|-------------|------------|---------------------------|------|-----------------------|---------------|------------------|-----------------------|----------------|------------|-------------|
| Transcriptome | SPLit-seq | Plated-based, Illumina NextSeq | 2018 | Not needed            | 3'            | Ligation of bar-coded RT primers | PCR                  | Microliter | High       | [8]         |
| SCI-RNA-seq  | Plate-based, Illumina NextSeq 500 | 2017 | Not needed            | 3'            | Barcoded RT primers | PCR                  | Not needed | High       | [17]        |
| Seq-well     | 10X Genomics, Illumina NextSeq 500 | 2017 | Droplet               | 3'            | Barcoded RT primers | PCR                  | Nanoliter  | High       | [191]       |
| inDrop       | Not mentioned | 2015 | Droplet               | 3'            | Barcoded RT primers | In vitro transcription | PCR                  | Microliter | High       | [192]       |
| Drop-seq     | 10X Genomics, Illumina NextSeq 500 | 2015 | Droplet               | 3'            | Barcoded RT primers | PCR                  | Nanoliter  | High       | [193]       |
| Microwell-Seq | Plate-based, Illumina HiSeq | 2018 | FACS                  | 3'            | Barcoded RT primers | PCR                  | Microliter | High       | [18]        |
| MARS-seq     | Plated-based | 2014 | FACS                  | 3'            | Barcoded RT primers | In vitro transcription | PCR                  | Microliter | High       | [194]       |
| CEL-seq 2    | Fluidigm C1, Illumina TrueSeq | 2016 | FACS                  | 3'            | Barcoded RT primers | In vitro transcription | Microliter | High       | [195]       |
| SMART-Seq 2  | Plate-based, Illumina HiSeq 2000 | 2013 | FACS                  | Full length   | Library PCR with barcoded primers | PCR                  | Microliter | Low        | [196]       |
| Genomics     | TARGET-seq | Plate-based, Illumina NextSeq 500/S 50 | 2019 | FACS                  | 3' and full-length | Barcoded RT primers | PCR                  | Microliter | High       | [53]        |
| Epigenomics  | CoBATCH    | 10X Genomics; Illumina HiSeq X | 2019 | FACS                  | Full length   | Barcoded PAT transposase | PCR                  | Microliter | High       | [197]       |
| scATAC-seq   | 10X Genomics, Illumina NextSeq 500 | 2013 | FACS                  | full length   | Barcoded primers | PCR                  | Microliter | High       | [198]       |
| Transcriptomics, proteomics | CITE-seq | 10X Genomics, Illumina HiSeq 2500 | 2017 | Droplet               | 3'            | Barcoded RT primers | PCR                  | Microliter | High       | [199]       |
| REAP-seq     | 10X Genomics, Illumina HiSeq 2500 | 2017 | FACS                  | 3'            | Barcoded RT primers, DNA-bar-coded antibodies | PCR                  | Microliter | High       | [200]       |
| INS-seq      | 10X Genomics, Illumina NextSeq 500 | 2020 | FACS                  | 5'            | Barcoded RT primers | In vitro transcription | PCR                  | Microliter | High       | [66]        |

RT: reverse transcription; SPLit-seq: split-pool ligation-based transcriptome sequencing; SCI-Seq: single-cell combinatorial indexed sequencing; FACS: fluorecence-activated cell sorting; MARS-seq: massively parallel single-cell RNA sequencing; inDrop: indexing drop RNA sequencing; scATAC-seq: single-cell transposase-accessible chromatin using sequencing; CoBATCH: combinatorial barcoding and targeted chromatin release; PAT: Tn5 transposase to protein A; CITE-seq: cellular indexing of transcripts and epitopes by sequencing; REAP-seq: RNA expression and protein sequencing assay; INS-seq: intracellular staining and sequencing.
as the inability to decipher the changing details of tumor subtypes, which contributes to tracking the spread pattern and key genes in lung cancer. These novel findings indicated the potential for developing targeted therapy and improving the clinical management of lung cancer in patients with KRAS mutations [41]. Another study in which scRNA-seq and high-confidence clonal tracing were combined demonstrated the first detailed characterization of leukemic stem cells, shedding new light on the understating of leukemia oncogenesis and treatment [42].

Single-nucleus RNA sequencing (snRNA-seq) dates back to 2013, when Grindberg found that it was difficult to dissociate integrated cells from brain tissue [43]. Div-seq and DroNc-seq have been used to resolve the difficulty in identifying rare neural cells and obtaining integrated cell types [44, 45]. At the same time, researchers have conducted snRNA-seq analysis of brain tissues in autopsies to expand the cell landscape retrieved from scRNA-seq data, demonstrating that frozen samples can be analyzed by snRNA-seq [7]. Currently, snRNA-seq has been widely utilized for different tissues and cell types, such as the kidney, heart, lung, pancreas, and, especially, brain tissue [46–50]. Compared with scRNA-seq, snRNA-seq has several advantages. First, snRNA-seq can be utilized to analyze valuable frozen samples, as the nuclear membrane may remain integrated, unlike the cell membrane in frozen tissues [51]. Second, snRNA-seq does not introduce artificial transcriptional stress responses or transcriptional bias, which may be induced by single-cell isolation in scRNA-seq, thus reflecting the real transcriptional status. Third, snRNA-seq can avoid the loss of specific cell types due to different vulnerabilities to proteases. Fourth, the preparation of a single nucleus is simpler than that of a single-cell suspension, which can minimize the generation of pseudocell populations induced by enzymatic hydrolysis and mechanical pressure.

SnRNA-seq has been widely utilized to analyze brain tumors because it is difficult to obtain fresh brain tissue for research, and the majority of samples are frozen. In 2020, researchers from MIT conducted scRNA-seq and snRNA-seq analyses of fresh or frozen tumor samples and evaluated the sequencing results with respect to cell and nuclear quality, cellular composition and other indicators. The comparison indicated that the two sequencing technologies detected similar cell types with distinct cellular proportions among different tissues. For example, the proportion of immune cells was higher, and the parenchymal cells (e.g., neural crest and neuroendocrine cells) were significantly reduced in neuroblastoma upon analysis by scRNA-seq. However, the proportion of substantial cells (especially malignant cells) was higher, while distinct immune cells were significantly reduced or even absent in the snRNA-seq data. Most importantly, significantly fewer neurons were identified by scRNA-seq than by snRNA-seq, which demonstrates the great potential of snRNA-seq in deciphering the landscape of brain tumors [52]. SnRNA-seq can obtain intron-region and intergene-region sequencing data, enabling cell type identification at a higher resolution and providing relatively richer gene information. However, the amount of RNA in a single nucleus is still significantly lower than that in whole cells, which suggests that snRNA-seq may not be appropriate for immune cell studies.

**Genomics**

Single-cell DNA sequencing has not yet made the transition to high-dimensional analysis due to its high cost. Therefore, the more economic method is to apply bulk sequencing first, followed by targeted single-cell DNA sequencing of the mutations or variations of interest. For example, TARGET-seq, which integrates genomic DNA and coding DNA genotyping, achieves good coverage across key mutation hotspots and enables the highly sensitive analysis of mutations within single cells. However, TARGET-seq relies on an analysis of known mutations and does not support the identification of new mutations [53]. Additionally, the computational method Cardelino integrates clone tree information from bulk exome sequencing and infrequent variant alleles from scRNA-seq, delineates phenotypic variations between clones and has revealed DEGs between cancerous and healthy skin tissues involved in the cell cycle and proliferation pathways in [54].

**Epigenomics**

Epigenetic dynamics can also be detected by single-cell sequencing technologies, such as chromatin immunoprecipitation sequencing (ChIP-seq) and assays for transposase-accessible chromatin using sequencing (ATAC-seq) [55]. In applying ATAC-seq to T cell receptor (TCR) research, transcript-indexed ATAC-seq (T-ATAC-seq) was reported to delineate the TCR specificity and epigenomic state of single T cells in cutaneous T cell lymphoma [56]. Furthermore, researchers introduced single-cell Cleavage Under Targets and Tagmentation (CUT&Tag) technology to probe the histone modification landscape in sequences including promotors, enhancers and gene bodies, as well as their dynamic regulatory interactions and single-cell chromatin occupancy, with high sensitivity and throughput within single cells [57].

To understand genome organization, researchers have used in situ genome sequencing (IGS) as a method for simultaneous in situ sequencing and imaging of genomes.
within intact single cells. IGS, which includes in situ genomics DNA library construction, in situ sequencing, amplicon dissociation, PCR and ex situ sequencing of amplicons and spatially localized sequences, reveals the precise localization of specific DNA sequences. IGS clearly provides a valuable opportunity for addressing intensive biological questions, such as the relationships between genome architecture and diseases [58]. Moreover, another study combined high-resolution multiple annealing and looping-based amplification cycles for digital transcriptomics (MALBAC-DT) and diploid chromatin conformation capture (Dip-C) to delineate transcriptomics dynamics and the three-dimensional genome architecture in single brain cells. This novel method could specifically decipher the roles of transcriptomics and genome architecture, as well as the interactions between function, anatomy, transcription and cell types in tumorigenesis and progression [59].

**Proteomics**

Proteins represent the main functional machinery of cells, so deciphering the expressed proteome at the single-cell level has attracted great interest. Mass spectrometry is the basis for proteome detection and quantification; however, it is suitable for only the most abundant of proteins. Researchers have improved the procedures used for protein preparation and isolation, thus decreasing protein loss and facilitating more in-depth quantitative proteomics sequencing at a single-cell resolution. Mass cytometry by time of flight (CyTOF), which relies on metal isotope-labeled antibodies conjugated with specific signal molecules on the surface or inside cells for immunolabeling, allows the profiling of 100 distinct proteins in single cells. Imaging mass cytometry (IMC) was developed based on immunohistochemistry with metal-labeled antibodies, and CyTOF. IMC can simultaneously analyze up to 40 protein markers and their spatial architecture and interactions, information that would be lost by traditional tissue lysis to single cells [60]. Importantly, IMC can be performed with paraffin-embedded tissue sections, so it can be applied for retrospective analyses of patient cohorts whose outcomes are known, eventually benefitting personalized medicine. Another single-cell proteomics sequencing technology is liquid chromatography–mass spectrometry (LC–MS), a bioanalytical method for the quantitative analysis of proteins that is widely applied in biopharmaceutical drug development and drug toxicology studies. Recently, single-cell proteomics by mass spectrometry (SCoPE-MS) was introduced to quantify multiplexed single-cell proteomes [61]. As expected, single-cell proteomics sequencing will change the landscape of investigative pathology, particularly when used in coordination with multiomic platforms, such as transcriptomic and proteomic data, at a single-cell resolution.

**Multiomics**

Progress in sequencing has enabled the integration of several sequencing technologies to delineate the TME and interactome within a single cell. First, simultaneous quantification of the DNA–protein interactome and transcriptome profile in a single cell would help researchers understand the transcriptional changes that occur when DNA binds a protein of interest, and such quantification has been realized by scDam&T-seq [62]. Second, concurrent sequencing of the transcriptome and targeted genomic regions (e.g., CORTAD-seq, G&T-Seq, and DR-Seq) within the same single cell can provide good coverage of the targeted genomic loci crucial for SNVs, deletion mutations and CNVs, which are responsible for resistance to targeted therapy in lung cancer [63]. The DNA methylome and mRNA transcriptome were simultaneously analyzed using scMT-Seq and scM&T-seq. Clone alignment statistically integrates independent single-cell RNA and DNA sequencing data [64]. Third, a recently reported integrative pipeline including 3D imaging based on the rapid clearing agent FUnGI was applied in breast tumors and revealed a significant reduction in tumor clones during oncogenesis, with the luminal progenitor found to be a key cell of origin [65]. LSR-3D imaging, together with multicolor lineage tracing and molecular analysis, provides essential visual and spatial information related to the tumor to study biological processes, highlighting the inherent plasticity of tumors. Fourth, several technologies, such as CITE-seq, REAP-seq and IN-seq, contribute to delineating the transcriptome and proteome at the same time [66].

**Analysis of single-cell sequencing data**

Single-cell sequencing is widely used to detect DEGs and can detect key signature genes during tumor progression. Several bioinformatics tools are available to mine scRNA-seq data and provide valuable insights. For example, mixed isolated cells could be hierarchically clustered into various subsets based on DEGs along the pseudotime or CNVs, which can be used to construct clonality trees, as observed in medulloblastoma [67]. Second, SCENIC analysis based on gene expression levels could reveal the dynamic interactions between genes within single cells, construct a gene regulatory network and reveal the regulatory changes during phenotype switches. Third, analysis of enriched gene ontology terms and pathway analysis based on Kyoto Encyclopedia of Genes and Genomes could delineate the expression of genes involved in specific signaling pathways associated with tumorigenesis, the cell cycle, epithelial-to-mesenchymal transition
(EMT) and immune responses among various subclusters. Notably, when expression information is combined with certain cell types, we can decipher the functions of the cell types during processes in tumor development, such as angiogenesis and tissue remodeling [68].

**Applications of single-cell sequencing in cancer biology**

**The cancer cell atlas and malignant cell heterogeneity**

In addition to the Human Cell Atlas, single-cell sequencing technology provides an unprecedented opportunity to decipher the functional states of single cancer cells. The accumulation of increasingly abundant single-cell sequencing data enabled establishment of The Cancer Cell Atlas, which covers a spectrum of cancers (Table 2). For example, Microwell-Seq contributed to cellular hierarchy construction and clonal heterogeneity deciphering in normal bone marrow and acute myeloid leukemia [69]. By integrating clinical pathological information and single-cell sequencing data, novel diagnostic and prognostic biomarkers and potential therapeutically relevant cell types or states could be deciphered [70]. In conclusion, The Cancer Cell Atlas can provide reference information for neoadjuvant therapy, especially for those for which baseline guidance is lacking [71].

The TME, which comprises cellular and noncellular components, plays crucial roles in tumorigenesis, progression, invasion, metastasis and drug resistance. These components orchestrate a tumor-promoting and tumor-inhibiting microenvironment that modulates tumor growth and influences tumor evolution, in which heterogeneity is also involved. The molecular basis for heterogeneity manifests as distinct malignant subpopulations based on structural variations, chromosomal rearrangement events, epigenetic modifications and gene expression signatures [72–77]. Moreover, nongenetic intratumor heterogeneity is a major predictor of phenotypic heterogeneity and evolutionary dynamics, rather than genomic features alone, in lung cancer [78]. However, heterogeneity constitutes the main obstacle to developing effective therapeutics; thus, deciphering the tumor tissue heterogeneity will substantially contribute to improving our understanding of the underlying mechanisms and developing precise therapies in clinical trials. Interestingly, recent findings showed that heterogeneity is stable over time across replicates of the same culture, strongly suggesting a regulated rather than a stochastic process, as described previously [79].

Compared to traditional bulk RNA sequencing, which reflects the average profiles of gene mutation and expression, scRNA-seq examines the multiomics features of individual cells, thus mapping the TME among various tumors, such as breast cancer [80]. These scRNA-seq data provide supporting evidence for accurate molecular subtyping and precise treatment (Fig. 1).

**Identification of dynamic gene expression profiles during tumor progression**

Single-cell sequencing can delineate changes in gene expression during tumor progression. Integrative single-cell sequencing of adjacent normal tissues and adenomas at different stages in patients comprehensively showed genomic alterations, clonal architecture and metabolic dynamics during tumorigenesis, providing insights into the inhibition of tumor progression [81]. For example, an evolutionary trajectory including the carcinogenesis of basal cells and activation of Wnt, followed by differentiation into luminal-like cells, was revealed in salivary gland squamous cell carcinoma [82]. Another example is the transformation of familial adenomatous polyposis to adenocarcinoma. Chen et al. discovered an intermediate epithelial–mesenchymal status, indicating that malignant cells retain epithelial characteristics while undergoing rapid migration in breast cancer [83]. A study of oncogene-induced senescence suggested a new mechanism of the tumor suppressor response to oncogene activation [84]. Interestingly, chromosome remodeling, including interwoven chromosome breakage–fusion–bridge cycles, micronucleation events and chromothripsis episodes, might also drive tumor evolution and cancer-associated thrombosis [85, 86].

**Identification of novel subpopulations, cell states and phenotype switches**

Individual tumor cells tend to primarily cluster according to their patient origin, which is not surprising because each tumor has a specific evolutionary trajectory with interpatient heterogeneity. Meanwhile, scRNA-seq can cluster cells based on cell type with t-distributed stochastic neighbor embedding (t-SNE), which is an algorithm designed to deconvolve and visualize high-dimensional scRNA-seq data in an unsupervised manner. Principal component analysis (PCA) and canonical correlation analysis order the cells in a gradient to interrogate the features of the clusters. Generally, the cell clusters compromise malignant tumor cells, stromal cells (epithelial cells, endothelial cells, and cancer-associated fibroblasts (CAFs) and immune cells. Further subpopulation clustering contributes to defining rare subpopulations or a spectrum of cellular states of malignant cells. By combining an analysis of signaling pathways, we were able to identify the most malignant subtype associated with a poor prognosis, which may provide insights into targeted therapy for this subtype. Recently, scRNA-seq research identified melanoma cells in an intermediate state and a malignant cell subset with unique characteristics among pancreatic,
Table 2  Establishment of the Cancer Cell Atlas by single-cell sequencing technologies

| The atlas | Methodology | Key findings | References |
|-----------|-------------|--------------|------------|
| Cancer specific | Spatial atlas of LUAD evolution | Single-cell RNA sequencing | Deciphered the geospatial evolution of cellular lineages, states and transcriptional features from normal tissue to LUAD. They also found that CD24 can mediate protumor phenotypes | [201] |
| | Ecosystem atlas in breast cancer | Single-cell RNA sequencing | Constructed the transcriptional atlas of the evolution trajectory from normal breast and preneoplastic BRCA1(±) tissue to various subtypes of breast cancer, highlighting the significant heterogeneity in microenvironment | [202, 203] |
| | Infiltrated B cells in TNBC | Single-cell RNA sequencing and antigen receptor profiling | The presence of infiltrated B lymphocytes indicated the local differentiation within breast tumors and revealed the positive correlation between B cells and survival via potential immunosurveillance | [204] |
| | T cell atlas in gliomas | Single-cell RNA sequencing | Provided the landscape of tumor-infiltrating T cells of IDH wild-type and mutation glioma and identified CD161 as an immunotherapy target | [205] |
| | Immune cell atlas in PDAC | Single-cell RNA sequencing | Established the immune cell atlas in PDAC, which acts as a reference to evaluate the immune landscape and potential effect of immunotherapy | [71] |
| | Immune cell atlas in ESCC | Single-cell RNA sequencing and TCR sequencing | Demonstrated the dynamics of various immune cells along tumor progression and indicated several immunosuppressive mechanisms | [206] |
| | Cellular hierarchy atlas in AML | Microwell-Seq and SMRT-seq | Revealed the AML landscape and proposed a ‘cancer attractor’ phenotype, which may help define the AML progenitor cell associated with prognosis | [69] |
| | Pancancer atlas | CancerSEA | Single-cell RNA sequencing | Provided a user-friendly database of 14 functional states of tumor cells (including stemness, invasion and EMT). It also provided the functional states associated PCG/inRNA repertoires among cancers | [207] |
| | CD8+ T cell atlas | Transposase-accessible chromatin sequencing, RNA sequencing | Defined the differentiation trajectory of CD8+ T cells toward dysfunction and revealed the underlying transcriptional drivers across various tumors, including melanoma and HCC | [208] |
| | TIM atlas | Single-cell RNA sequencing | Revealed the similarity and distinction of TIMs, including mast cells, DCs and TAMs, across 15 tumors and revealed the association with somatic mutations and gene expression | [209] |
| | HLA atlas | Immunoaffinity purification and liquid chromatography mass spectrometry | Delineated the HLA-I and HLA-II immunopeptidomes from tumor and benign human tissue samples, enabling the balanced comparison of HLA ligand levels and thus facilitating immunotherapy | [210] |
| | Fibroblast atlas | Single-cell RNA sequencing | Demonstrated that fibroblast transcriptional states are conservative across species and in different diseases | [211] |

LUAD: lung adenocarcinoma; IDH: isocitrate dehydrogenase; TIM: tumor-infiltrating myeloid cells; TAM: tumor-infiltrating macrophages; HLA: human leucocyte antigen; PDAC: pancreatic ductal adenocarcinoma; TNBC: triple-negative breast cancer; ESCC: esophageal squamous cell carcinoma; AML: acute myeloid leukemia; SMRT-seq: single-cell single-molecule real-time sequencing
Key genes identified during cellular transitions may be involved in transcriptional or posttranscriptional regulation and have the potential to serve as therapeutic targets. Among various malignant tumor cells, an analysis of the mean-squared displacement, velocity and maximal distance traveled contributes to the prediction of the migratory capacity of certain subpopulations, thus providing insights into the mechanisms of tumor metastasis. Unsupervised analyses of the transcriptional trajectory of malignant cells from Monocle2 may be useful for analyzing the dynamics of tumors. For example, malignant osteoclasts are split into progenitor cells, immature cells and mature cells in osteosarcoma [91].

The TME determines phenotypic features, thus enabling the best adaptation to the external environment. For example, malignant cells near the tumor tissue present characteristics of metastasis and invasion, while the malignant cells within the tumor maximize their proliferative ability by activating metabolism. Similar to next-generation sequencing, scRNA-seq can reveal phenotypic dynamics at different stages of tumor progression. Comparison of sequencing data from primary tumor lesions at different clinical stages, recurrent lesions, distant metastatic lesions and corresponding healthy tissue contributes to our understanding of the phenotypic changes that occur during tumor progression and metastasis, such as those in glioma, sarcoma, colorectal cancer and bladder cancer [92–94]. Phenotypic heterogeneity might be driven by transcriptomic heterogeneity through its effects on cancer-associated pathways. For example, a recent study revealed that malignant osteoblastic cells, which are characterized by high mesenchymal marker and transcription factor expression, may originate from any type of cell along the osteogenic differentiation pathway from mesenchymal stem cells in osteosarcoma [91].
MUC6 + TFF2 + spasmolytic polypeptide-expressing metaplasia, which may originate from gastric chief cells, is a state of precancerous lesions in gastric cancer [89]. In addition, oxidative phosphorylation plays a key role in breast cancer metastasis based on a comparison of primary tumors and micrometastatic tissue [95]. More key findings on the cell map of malignant cells are listed in Table 3.

CTCs and CSCs
CTCs, rare cancer cells that slough off from primary tumor tissues and circulate in the bloodstream, are thought to act as ‘seeds’ that initiate cancer progression and metastasis [96, 97]. Molecular analysis of CTCs at a single-cell resolution allows the generation of robust, rich genome and transcriptome datasets, thereby providing biomarkers to understand the underlying mechanisms of progression, prognosis, evaluation dynamics and therapeutic response [98–100]. CTCs and circulating tumor DNA have been approved by the US Food and Drug Administration as noninvasive liquid biopsies, and extracellular vesicles, circulating tumor RNA and tumor-educated platelets have been identified as novel constituents with promising potential in cancer management [99]. New platforms (e.g., Cheimera X-il20 and Hydro-Seq) were developed to overcome current limitations in the detection of CTCs, including cell loss, a high false-positive detection rate, CTC scarcity and substantial contamination with blood cells [101, 102].

Based on accumulating evidence, CTCs travel in clusters rather than in isolation in the peripheral fluid [103]. The ability to provide insight into CTC subtypes and intravascular interactions with other blood cells may help elucidate the mechanisms of tumor progression and prognosis. In breast cancer, researchers identified 2 CTC subpopulations with differences in estrogen responsiveness and EMT, as well as the interactions between CTCs and peripheral monocytes [104]. Moreover, transforming growth factor β secreted by activated platelets is associated with an EMT phenotype in CTCs, contributing to escape from immune surveillance [97]. Furthermore, another scRNA-seq study revealed the presence of a neutrophil-CTC niche in peripheral blood. Neutrophils from this niche were found to express genes associated with the cell cycle and cytokines, such as TNF-β, OSM, IL-1β, IL-6 and Vcam1, at high levels, and these genes may be involved in niche formation [105]. Based on this finding, the CTC-neutrophil clusters in patients may be useful as a positive biomarker to predict disease outcomes, providing novel insights into targeted therapy for cancer (Fig. 2). Another study reported that the perivascular niche may act as a niche for various subtypes of brain tumor stem-like cells, while the microvascular tracks may serve as a path for tumor migration and therapeutic resistance [106].

CSCs exhibit self-renewal and multidirectional differentiation, and cancer stemness can be induced by chemotherapy rather than pure selection [107, 108]. Several signaling pathways (e.g., WNT, NOTCH, HIPPO, and RAS), hypoxia, and pathways related to DNA repair and the cell cycle were shown to be functionally associated with the induction of cancer stemness [109–111]. More recently, low proteasome gene expression was reported to promote the formation of CSCs via the NOTCH signaling pathway in malignancies [112]. Inhibition of the proteasome drove cancer cells to adopt a CSC state via the TGF-β signaling pathway [113, 114]. A subpopulation of CD24+CD44+ cells was identified and found to be associated with cancer stemness in HCC [114]. Intriguingly, CSCs from distinct cancers exhibit variability with respect to surface markers, which increases the difficulty of developing CSC-targeted therapies [115].

Stromal heterogeneity
CAFs are major components of stromal cells in several tumors and influence the stroma by secreting excess extracellular matrix and interfering with collagen crosslinking, thus modulating tumor stiffness and facilitating cancer progression [116–121]. For example, cadherin 11 promotes extracellular matrix deposition to support the growth of pancreatic carcinoma and resistance to gemcitabine [122]. Moreover, CAF-derived factors may alter the immune microenvironment by inhibiting immune effector cell activity and recruiting immune-suppressive cells, allowing cancer cells to evade immune surveillance [123–128]. A recent sequencing analysis separated CAFs into 3 main subgroups: myofibroblastic CAFs, inflammatory CAFs and antigen-presenting CAFs. Specifically, a recent study revealed recurring, patient-dependent expression programs in stromal cells from primary hepatic duct carcinoma and hepatic metastatic tumors [129, 130].

Immune cell heterogeneity and the immune microenvironment
The tumor immune microenvironment, which is an important component of the TME, exerts profound effects on the immunotherapeutic response and clinical outcome. The map of the immune atlas describes a growing portfolio of immune cells, including lymphocytes, monocytes, macrophages, natural killer cells and dendritic cells (DCs). Indeed, subpopulations comprising the immune microenvironment vary during tumor progression. For example, stromal and immune cells undergo dynamic ontological and functional changes that create a protumor and immunosuppressive microenvironment.
| Tumor       | Technology            | Platform      | Key findings                                                                                                                                                                                                 | References |
|-------------|-----------------------|---------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| PDAC        | scRNA-seq, trajectory analysis | 10X Genomics  | Identified 11 subpopulations of malignant tumor cells, including a subset of malignant ductal cells with unique proliferative features associated with the inactivation of tumor-infiltrating T cells                                                                 | [90]       |
| PDAC        | scRNA-seq, trajectory analysis | 10X Genomics  | Identified 6 acinar metaplastic cell subpopulations during the progression from preinvasive stages to tumor formation in a mouse model                                                                                                                                   | [212]      |
| LUAD, LUSC  | Bulk and scRNA-seq    | 10X Genomics  | Revealed that nongenetic heterogeneity is a major predictor of phenotypic heterogeneity                                                                                                                                                                             | [78]       |
| LUAD        | scRNA-seq             | 10X Genomics  | Identified 19 tumor-specific markers as candidate markers for the detection of extraordinarily rare circulating tumor cells                                                                                                                                          | [213]      |
| lung cancer | Single-cell sequencing | CyTOF         | Revealed that AXL inhibition suppresses SMAD4/TGFβ signaling and induces JAK1/STAT3 signaling pathways, and AXL functions via CD133-mediated cancer stemness and hybrid EMT features in patients with advanced-stage tumors | [214]      |
| GGN-ADC, SADC | scRNA-seq, flow cytometry | 10X Genomics  | Revealed the downregulation of signaling pathways associated with angiogenesis and cell proliferation, low expression of collagens of fibroblasts and activated immune cells in GGN-ADC                                                                 | [215]      |
| melanoma    | scRNA-seq, bulk RNA-seq, ATAC-seq | 10X Genomics  | Confirmed the intermediate state of melanoma cells, which is governed by SOX6, NFATC2, EGR3, ELF1 and ETV4 and regulated by a gene regulatory network                                                                                                              | [79]       |
| GA          | scRNA-seq             | 10X Genomics  | Identified 5 subtypes of malignant tumor cells, 3 of which corresponded with the histopathological features of Lauren’s subtypes, while 1 was associated with the GA-FG-CCP                                                                                                      | [216]      |
| EGC         | scRNA-seq             | 10X Genomics  | Revealed that the glandular mucous cells tended to acquire an intestinal-like stem cell phenotype during metaplasia; HSE6 may help identify early-stage tumors                                                                                                               | [216]      |
| AML         | scRNA-seq, next-generation sequencing | 10X Genomics  | Identified 3 leukemia subpopulations arrested at different stages of myeloid differentiation: CD34*CD117* blasts (blocked in G0/G1 phase), CD34*CD117** blasts and partial maturation myeloid cells                                                                 | [217]      |
| MM          | scRNA-seq             | Fluidigm C1   | Identified 4 groups of malignant cells; the L1 group from MGUS expressed the lowest levels of genes involved in oxidative phosphorylation, while the L4 group from MM displayed the highest expression                                                                                     | [218]      |
| NEPC        | scRNA-seq             | 10X Genomics  | Revealed that focal neuroendocrine differentiation exclusively originates from luminal-like malignant cells and identified differentiation-association signature genes                                                                                                            | [219]      |
| medulloblastoma | scRNA-seq              | 10X Genomics  | Identified OLIG2-expressing glial progenitors as transit-amplifying cells at tumor onset, and they are enriched in therapy-resistant and recurrent medulloblastoma                                                                                                        | [220]      |
| glioma      | scRNA-seq             | 10X Genomics  | Identified Zfp361 as a key gene for glioma growth, various transitional intermediate states and corresponding developmental lineages                                                                                                                          | [221]      |
| glioblastoma| scRNA-seq             | 10X Genomics  | Identified key genes involved in NSC transformation into tumor-promoting cells; NSCs may promote metastasis via extracellular vesicles                                                                                                                                   | [222]      |
| glioblastoma| scRNA-seq             | 10X Genomics  | Identified RAD51AP1 as an independent prognostic factor and a potent mediator of EGFRvIII signaling                                                                                                                                                                       | [223]      |
| ESCC        | scRNA-seq, bulk sequencing | SMART-Seq 2  | Identified genes associated with radioresistance, including autophagy-related 9B, DNA damage-inducible transcript 4, myoglobin and plasminogen activator tissue type                                                                                     | [224]      |
Resident myeloid cells are gradually replaced with mono-
cyte-derived macrophages and DCs upon T cell exhaus-
tion in metastatic lung adenocarcinoma [68]. ScRNA-seq was
applied to study promotion of the immunosuppressive
microenvironment through changes such as the
increased expression of protein disulfide isomerase fam-
ily A member 3 (PDIA3) associated with PTEN loss and
EGFR amplification in gliomas [131]. Additionally, the
cellular composition is associated with prototypic genetic
lesions, as observed for the abundance of FLT3-ITD and
abundant progenitor-like cells in acute myelocytic leu-
kemia [9]. Research on the mechanisms of tumor het-
erogeneity has the potential for use in stratified targeted
therapy according to tumor category and stage. Moreo-
ver, we have summarized recent findings of the tumor
immune microenvironment in Table 4.

**T cells**

Distinct types of T cells orchestrate antitumor T cell
responses to fight malignancies in cooperation with
| Tumor | Technology | Platform | Key findings | References |
|-------|------------|----------|--------------|------------|
| osteosarcoma | scRNA-seq | 10X Genomics | Identified proinflammatory FABP4+ macrophage infiltration in lung metastatic lesions and revealed that TIGIT blockade enhances the effects of the primary CD3+ T cells | [91] |
| LUAD, LUSC | Bulk and scRNA-seq | 10X Genomics | Revealed that the neoantigen burden is negatively associated with immune cell infiltration and affects evolutionary dynamics | [78] |
| RCC | scRNA-seq | 10X Genomics | T cell exhaustion is a key factor that represses immunity, PD-L1, LAG3, TIM-3 are potential targets | [56] |
| RCC | scRNA-seq, flow cytometry | 10X Genomics | The baseline and dynamic renal cell carcinoma tumor burden influence the T cell repertoire; baseline TCR β-China is associated with the prognosis | [154] |
| CAC | scRNA-seq, flow cytometry | 10X Genomics | Identified the transcriptomic signatures of CD4+ T cells between antitumor and anti-viral infection responses | [155] |
| cHL | scRNA-seq, imaging mass cytometry | CyTOF | Identified LAG3+ Tregs in MHC-II-negative classic HL | [134] |
| HCC | scRNA-seq | 10X Genomics, CyTOF | Identified the trajectory and functional analysis of CD4/CD8 double-positive T cells enriched in L regions with synergetic expression of PD-1/HLA-DR/ICOS/CD45RO and certain transcription factors | [142] |
| HCC | scRNA-seq | 10X Genomics | Identified the abnormal immune cells content dynamics in relapse tumors | [137] |
| HCC | scRNA-seq, flow cytometry | 10X Genomics | Identified the M2 macrophages that expressed CCL18 and CREM at high levels, as well as XCL1 +activated T cell subsets as a 'pre-exhaustion' status | [136] |
| HCC | scRNA-seq | 10X Genomics, SMART-Seq 2 | Identified the enrichment of MIAT in FOXP3+ CD4+ T cells and PDCD1+-GZMK+CD8+ T cells, which modulates the expression of distinct genes (JAK2, SLC6A6, KCND1, MEIS3 or RIN1) to contribute to immune escape | [228] |
| CTCL | scRNA-seq | 10X Genomics | Identified the heterogeneity of malignant T cells | [229] |
| CTCL | scRNA-seq, flow cytometry | 10X Genomics | Identified the FOXP3+ T cells transiting to GATA3+ or IKBZ2+ tumor cells during clonal evolution, which could be used to classify the tumor stage and predict early-stage progression | [230] |
| Osteosarcoma | scRNA-seq | 10X Genomics | Revealed that TIGIT blockade enhances the cytotoxic effects of the primary CD3+ T cells on advanced osteosarcoma | [91] |
| Lung cancer | scRNA-seq, flow cytometry | 10X Genomics | Compared the cancer cells and CD3+ T cells between GGN-ADC and SADC | [215] |
| Breast cancer | scRNA-seq | 10X Genomics | Identified the characteristics of myeloid-derived suppressor cells | [231] |
| PDAC | scRNA-seq | 10X Genomics | Identified a subset of ductal cells with proliferative features associated with inactivating T cells | [49] |
| GBM | Single-cell and bulk RNA sequencing | 10X Genomics | Revealed the molecular determinants, including TLE2 and IKBZ2, required to improve the CAR antitumor efficacy; identified the genes sensitive to CART therapy | [232] |
other immune cells. Tumor-infiltrating lymphocytes (TILs) are a highly heterogeneous population in terms of cell type composition, molecular subtype, gene and protein expression and functional properties at different stages; thus, a systematic interrogation of TILs is key to the development of immunotherapies [132]. Importantly, scRNA-seq provides information about cellular distribution, clonal amplification, migration and evolution dynamics, as well as a map of the immune landscape through TCR analysis. According to recent studies, some TILs, acting as ‘bystanders,’ are not capable of recognizing antigen-bound major histocompatibility complex (MHC) molecules and then attacking tumor cells, suggesting that the TIL content is not related to the predicted responsiveness of immunotherapy among tumors. Aoki et al. identified a disease-defining T cell subpopulation with high expression of LAG3, which functions to mediate immunosuppression in classic Hodgkin lymphoma [133]. In tumor tissues, regulatory T cells (Tregs) undergo abnormal changes in expression, such as the change in LAG3 expression observed in classic Hodgkin lymphoma, upregulated LAYN expression in FOXP3+Helios+Tregs, and changes in CCR8 and IL1R2 expression in HCC [134, 135]. In addition, the chronic remodeling of tumor antigens alters Treg cell frequencies and subsequently promotes the recurrence of HCC [136, 137].

T cells are the main components of the adaptive immune system responsible for antitumor immunity and responsiveness to immunotherapy. Single-cell analyses ignore the complex interactions between different cells, and by analyzing the correlations of ligand-receptor pair expression levels among various cell types, we can decipher the landscape of these cellular interactions [138, 139]. Heterodimeric TCRs that consist of two different subunits determine biological functions by interacting with various ligands, and the genetic recombination of subunits creates a diverse TCR repertoire [140]. Moreover, tumor neoantigens must be presented by MHCs and then recognized by TCRs on TILs. The combined use of scRNA-seq with TCR sequencing enables the identification of rare immune subpopulations and their potential functions and links T cell phenotypes with the specific TCR clonotypes of individual T cells. For example, the newly identified CD4+CXCL13+BHLHe40+Th1-like CD4+ subset might explain the difference in responses to anti-PD1 therapy in patients with colorectal cancer presenting with MSI and MSS, while PD-1\textsuperscript{high} CD4+CD8+ T cells are associated with prolonged survival in patients with HCC [141–143]. Integrated scRNA-seq and scTCR-seq analyses revealed the clonotypic expansion of effector-like T cells in tumors and tumor-adjacent tissues, even in peripheral blood. In addition, immune circulation, intratumor T cells are replenished with fresh, nonexhausted cells from outside the tumor instead of cells within the tumors [144].

**B cells**

Malignant B cells exhibiting specific transcriptomic profiles are mainly present in lymphoma. The newly identified continuum of cyclic germinal center B cell transitional states reveals the heterogeneity in follicular
lymphoma [145, 146]. However, B cell heterogeneity is somewhat determined by somatic mutations, indicating the induction of other mechanisms, including phenotypic diversity or epigenetic modifications [145]. Integrated single-cell sequencing and trajectory analyses also enabled researchers to decipher the evolutionary pathway of malignant B cell maturation, which is accompanied by the progressive loss of follicular and germinal center B cell gene expression programs (e.g., KMT2D, CREBBP and EZH2) [146]. Other researchers further explored the relationship between intratumor heterogeneity and treatment response using a combination of scRNA-seq with transcriptome-informed flow cytometry and identified subpopulation-specific drug sensitivity in nodal B cell lymphoma [147].

**Monocytes**

Myeloid cells, including tumor-associated macrophages (TAMs) and DCs, have been demonstrated to control tumor malignancy [148]. Myeloid cells exhibit changes in transcriptional pattern and infiltration extent and show great heterogeneity among various tumors. TAMs display noticeable plasticity in their phenotypic and functional properties after their derivation from the mononuclear phagocyte system. To the best of our knowledge, TAMs undergo polarized activation upon distinct exposure. Some single-cell sequencing studies demonstrated that the classically activated (M1) macrophage signature and alternatively activated (M2) macrophage signature could coexist in single macrophages, thus identifying various subsets of myeloid cells [136, 149]. Apart from the traditional M1/M2 activation paradigm in macrophages, scRNA-seq has revealed the complexity of macrophage expression profiling. For example, scRNA-seq with CITE-seq revealed that TAMs derived from microglia (Mg-TAMs) or classical monocytes (Mo-TAMs) exhibit a spectrum of transcriptional activation states. However, they exhibited a convergent angiogenic and T cell-suppressive capacity ex vivo in glioblastoma [149].

Although DCs represent only a small proportion of leukocytes, they play an important role via their strong antigen-presentation capacity. ScRNA-seq analysis of the intratumoral heterogeneity of DC subsets identified transcriptomic signatures and the prognostic value of DCs [150]. For example, LAMP3+ DC clusters, which migrate from tumors to hepatic lymph nodes, appear to be the most active immune regulators due to their secretion of the most distinct immune-related ligands and modulation of the phenotypes of lymphocytes [33]. These findings indicate that targeting specific TAM and DC subsets may hold significant diagnostic, therapeutic and prognostic potential.

**Immunotherapy**

In recent years, the development of immunotherapy has significantly enhanced cancer therapies, and immune checkpoint inhibitors (ICIs) have had tremendous effects on some advanced tumors [151]. However, the clinical responses to immunotherapy vary among different patients and cancer types, as evidenced by the limited clinical success rate in patients with HCC [152]. Furthermore, ICIs alone were reported to display limited efficacy, ranging from 15 to 30%, except in melanoma [153]. ScRNA-seq and various multimodal techniques derived from scRNA-seq are advancing our understanding of human tumor heterogeneity and the mechanisms that drive responsiveness and resistance to immunotherapies, thereby providing insights into potential combinational therapies for different cancers [36].

Exhausted T cells are characterized by the high expression of inhibitory receptors, including PD-1, CTLA-4, TIM3 and LAG3, and hierarchical loss of effector functions, which is the target of ICI therapy [154]. Activated CD8+ T cells that express XCL1 at high levels are characterized as in a potential “pre-exhaustion” status and may function by recruiting cDC1 cells [136]. Moreover, the heterogeneity of CD4+ T cells might partially explain their distinct responses to tumor antigens and viral infection [155]. Researchers have identified other immune cells that participate in immunotherapy. For example, lenvatinib presents antitumor activity by reducing TAM infiltration and activating the interferon pathway in HCC [156]. Improved vascularity was shown to result in an improved pancreatic ductal adenocarcinoma (PDAC) prognosis, possibly due to the increased infiltration of immune cells and/or delivery of drugs [157].

These profound results have contributed to the screening of specific targets for immunotherapy. By performing single-cell sequencing in patients treated with ICIs, we were able to analyze the specific transcriptional activity of ICIs or select neoantigens transcribed at a high level, enabling the design of precise therapy. By analyzing the heterogeneity of immune-related genes using scRNA-seq, we can design combination therapies that target various tumor neoantigens and thus improve clinical efficacy.

A comprehensive understanding of the immune cell composition and states is crucial to delineating the responsiveness and resistance to immunotherapies and could help in the design of novel targeted immune-modulating therapies. Notably, the identification of transcriptome-wide signatures associated with therapeutic response or resistance improves our understanding of the mechanisms of immunotherapy. Extending the transcriptional immune atlas of normal tissue to the TME could provide intriguing insights into the heterogeneity and distinct immunotherapeutic responses of a spectrum...
of tumors. For patients who are insensitive to immunotherapy (such as CTLA4 and PD1/PD-L1), single-cell sequencing might be able to analyze specific tumor tissues and elucidate the underlying mechanisms of resistance. For example, a new subset of macrophages with high CD73 expression was shown to be associated with a reduction in immune cell infiltration. Therefore, targeted therapy could combine CD73 blockers with PD-1/CTLA-4, a potential strategy of clinical significance [158]. Another example is the construction of an immune checkpoint gene network in patients with follicular lymphoma who were insensitive to CTLA-4/PD-1 therapy, which improved our understanding of the complex mechanisms underlying immune invasion and provided new insights into therapy design [145].

According to Darwinian theory, resistant cells are thought to arise from selection pressure on heterogeneous malignant cells. However, recent studies have shown that simple selection does not adequately account for late relapse, and resistance patterns (e.g., transcriptional reprogramming) may exist before treatment across a spectrum of tumors [159–163]. In a PD-1-resistant colorectal cancer patient with high microsatellite instability, biallelic loss of the beta2-microglobulin (β2M) gene was found to be associated with intrinsic resistance [164]. Moreover, a precise pattern, including decreased NF-kB-binding signatures, followed by a rapid reduction in the regulatory activity of transcription factors (e.g., EBF1, FOXM1 and IRF4), was revealed in chronic lymphocytic leukemia patients with ibrutinib resistance [165–167]. This approach disentangles the dispute over whether resistance is the result of selection or transcriptional adaption, providing valuable insight into the development of drug resistance and the application of stage-specific biomarkers. Nevertheless, epigenetic alterations, including those due to KDM5 histone demethylase activity, were identified as correlated with therapeutic resistance by Kunihiko [168].

scRNA-seq has also been used to explore the novel combination of immunotherapy with chemical or radiation therapy to improve clinical effects among patients with cancer and explore the relationship of resistance between distinct therapies [169, 170]. For example, radioresistant cells from basal breast cancer with a high tumor mutation burden, high degree of mutational microsatellite instability and activated NRF2 pathways exhibit a higher rate of PD-L1 positivity [171]. In TME-modulation strategies, traditional delivery systems limit drug retention times, and nanoparticles with unique physical properties and elaborate designs efficiently penetrate the TME and specifically deliver drugs to targeted components of the TME among a spectrum of tumors. However, researchers’ interest in recent years has increasingly focused on the toxicity of monoclonal antibodies. A recent study revealed the genes (e.g., SPP1, HMOX1, TIMP1 and NAMPT) associated with trastuzumab-mediated cardiotoxicity in breast cancer [172]. These findings are useful for identifying potential prognostic biomarkers and expanding the immunotherapy scope based on patient subtype and dominant immune cell crosstalk, paving the way for the use of combination therapy in patients with cancer.

Diagnosis
Cancers are traditionally diagnosed based on tissue origin and histologic features. Growing evidence has shown that molecular features influence the TME and thus alter clinical behaviors and responses to therapy. A better understanding of molecular features through identifying sensitive biomarkers, mutations or gene expression profiles will improve the diagnosis and targeted therapy of cancer in patients. For example, a malignant cell subpopulation dominating the metastatic stage was demonstrated to be a biomarker in lung cancer, while a tumor-associated microglia/macrophage-mediated EGFR/ERBB2 feedback-crosstalk signaling module was proven to outperform traditional gene biomarkers in glioma [68, 173]. Another potential diagnostic direction involves the molecular subtype among various tumors, such as bladder cancer and pancreatic cancer [174]. A recent study in bladder cancer correlated scRNA-seq data with previously known molecular subtype information (e.g., luminal-papillary, luminal-infiltrated, luminal, basal-squamous and neuronal) and revealed the correlation between molecular and clinical features, guiding molecular diagnosis and targeted therapy [175]. In addition, the detection of CTCs by single-cell sequencing technology contributes to early diagnosis and prognostic monitoring.

Treatment
Single-cell sequencing is widely utilized to measure the clinical effectiveness and safety of novel drugs in clinical trials. A search for ‘cancer’ and ‘single-cell sequencing’ on the http://clinicaltrials.gov Web site yielded 16 relevant clinical trial records (Table 5). Most of these records described phase 2 clinical trials. Single-cell sequencing can be used to explore dynamic regulatory networks and identify heterogeneous cellular behaviors in response to various chemical drugs or the irradiation of cell lines or tumor samples, such as esophageal squamous cell carcinoma samples [176]. The newly developed technique scPlex, which is based on Sci-Seq and nuclear hashing, has been used to decipher transcriptomic changes in millions of malignant cells toward distinct chemical drugs and the underlying mechanisms. Compared with traditional...
| NCT number     | Phase | Tumor                  | Title                                                                 | Status         | Primary outcome measures                                                                 | Single-cell sequencing-related outcome                                                                 | Enrollment |
|---------------|-------|------------------------|----------------------------------------------------------------------|----------------|----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|------------|
| NCT03117751   | Phase 2| Phase 3 acute lymphoblastic leukemia and lymphoma | Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma | Recruiting     | Event-free survival (EFS) of patients with ALL                                          | Single-cell sequencing to monitor somatic mutations in peripheral blood as patients undergo treatment         | 1000       |
| NCT04352777   | Phase 2 | breast cancer          | Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2+Breast Cancer | Recruiting     | Changes in serum estrogen (E1 and E2) levels compared to changes in the tumor immune cell repertoire and function in response to endocrine therapy and CDK 4/6 inhibition | Changes in tumor immune cell populations will be assessed using scRNA-seq                                  | 30         |
| NCT03984578   | Phase 2 | colorectal cancer      | Window of Opportunity Study in Colorectal Cancer                     | Recruiting     | Tumor immune gene expression signature|Pathological regression                                   | Relative proportion/percentage of different immune cell states or immune cell types as inferred from single-cell profiling | 50         |
| NCT04460248   | Phase 2 | diffuse large B cell lymphoma | Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naïve Patients With Diffuse Large B-cell Lymphoma (DLBCL) | Recruiting     | Complete response rate                                                               | scRNA-seq of tumor tissues                                                                       | 40         |
| NCT03921021   | Phase 2 | esophagogastric adenocarcinoma | Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma | Recruiting     | Overall response rate, as assessed by radiographic imaging                             | Change from baseline in the tumor-immune microenvironment measured using scRNA-seq                          | 41         |
| NCT04367025   | Phase 2 | gastric cancer         | Efficacy and Safety of Perioperative Chemotherapy Plus PD-1 Antibody in Gastric Cancer | Not yet recruiting | Major pathological response (MPR)                                                      | Differences in T cell gene expression were detected using scRNA-seq to screen people who were more sensitive to immunotherapy | 70         |
| NCT04656535   | Early Phase 1 | glioblastoma          | AB154 Combined With AB122 for Recurrent Glioblastoma                 | Not yet recruiting | Incidence of treatment-emergent adverse events [safety and tolerability] associated with the combination AB122 and AB154 in patients with recurrent glioblastoma | scRNA-seq of tumor and blood after exposure to AB154 with and without AB122                                | 46         |
| NCT number   | Phase  | Tumor                          | Title                                                                 | Status            | Primary outcome measures                                                                 | Single-cell sequencing-related outcome                          | Enrollment |
|-------------|--------|--------------------------------|----------------------------------------------------------------------|-------------------|------------------------------------------------------------------------------------------|------------------------------------------------------------------|------------|
| NCT03655444 | Phase 1| head and neck squamous cell    | Abemaciclib+Nivolumab in Patients With Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy | Terminated        | Phase I Only: Determine the recommended phase 2 Dose of abemaciclib combined with a fixed dose of nivolumab| Overall survival (OS) rate                                      | 6          |
|             | Phase 2| carcinoma                      |                                                                      |                   | scRNA-seq analysis of tumor tissue and blood obtained before and during treatment with abemaciclib and nivolumab |                                                                  |            |
| NCT04588038 | Phase 1| head and neck squamous cell    | NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery | Not yet recruiting| Proportion of treatment-related adverse events | Gene expression profiling using scRNA-seq | 10         |
| NCT03869034 | Phase 2| hepatocellular carcinoma       | TAI Combined With PD-1 Inhibitor in Locally Advanced, Potentially Resectable HCC | Active, not recruiting | Progression-free survival (PFS) assessed using RECIST 1.1 criteria | Biomarkers of treatment response by single-cell RNA sequencing   | 40         |
| NCT03407170 | Phase 2| melanoma                       | Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475–161/KEYNOTE-161) | Terminated        | Mean fraction of cytotoxic T lymphocytes (FCT) in participants who achieved a response compared with participants who experienced progression | Neoepitope sequencing will be generated based on scRNA-seq       | 1          |
| NCT03534635 | Phase 2| melanoma                       | Analysis of the Modulation of the Tumor Microenvironment by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS) | Recruiting        | Identification of biomarkers using genomics and proteomics tools (scRNA-seq, exome sequencing, and single-cell profiling), multiplexed immunohistochemistry and bioinformatics | Identification of biomarkers using scRNA-seq                    | 30         |
| NCT03743766 | Phase 2| melanoma                       | Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naive to Prior Immunotherapy in the Metastatic Setting | Recruiting        | Change in LAG3 expression | scRNA-seq                                                       | 42         |
| NCT04217317 | Phase 2| non-Hodgkin lymphoma            | CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma | Recruiting        | Number of participants who successfully complete the therapy regimen                  | Single-cell sequencing                                         | 12         |
Table 5 (continued)

| NCT number | Phase      | Tumor                                  | Title                                                                 | Status     | Primary outcome measures                      | Single-cell sequencing-related outcome                                                                 | Enrollment |
|------------|------------|----------------------------------------|----------------------------------------------------------------------|------------|------------------------------------------------|----------------------------------------------------------------------------------------------------------|------------|
| NCT04697940 | Phase 1|non-Hodgkin lymphoma                   | Decitabine-primed Tandem CD19/CD20 CART Cells Treatment in r/r B-NHL | Recruiting | Safety in phase 1                              | Analysis of CAR T cell populations from patients using single-cell sequencing to determine distinct subtypes and clonal expansion of infiltrating lymphocytes | 30         |
| NCT04495894 | Early Phase 1 | non-small-cell lung cancer and renal cell carcinoma | Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small-Cell Lung Cancer and Renal Cell Carcinoma | Recruiting | Incidence of blood transfusions among the ketorolac group | scRNA-seq                                                                                                  | 76         |
high-throughput chemical screens, sci-Plex can delineate more nuanced molecular mechanisms and reveal transcriptomic trajectories behind drug responses at a single-cell resolution with a lower cost [177].

Angiogenesis-targeted therapy has been demonstrated to play a key role in modulating tumor heterogeneity and tumor liver metastasis, and the underlying metastatic patterns were recently revealed by scRNA-seq [178–180]. The combination of VEGF blockade and tyrosine kinase inhibitors has shown promising clinical effects in advanced tumors, such as HCC and pancreatic neuroendocrine tumors [181, 182]. Complex growth patterns may explain why the antiangiogenic therapy efficacy varies among patients and thereby may function as a stratification method to recognize populations who might experience a benefit.

Conclusions

Single-cell sequencing has advanced at a very rapid speed, and emerging and powerful technologies will undoubtedly promote new levels of precision and accuracy in molecular cancer research, such as the tumor microenvironment and heterogeneity. Therefore, it significantly improved our understanding of cancer diagnostic stratification, biomarkers, precise treatment and prognosis prediction [183–188].

However, the limitations of single-cell sequencing should be recognized. First, scRNA-seq intrinsically shows that not all eukaryotic cells undergo transcription at a consistent basal rate. Transcription occurs in pulses; therefore, instant sequencing is unable to completely decipher the transcription map [189, 190]. Additionally, most sequencing methods are designed for 3′ or 5′ reads and are not sensitive to transcripts at low abundance. Second, scRNA-seq alone cannot correlate genotype and phenotype, suggesting the need for high-throughput, low-cost multiomic technologies to delineate the overall tumor tissue landscape. Third, batch effects derived from the use of different platforms and processing procedures and analysis on different days might exist. Such batch effects are extremely clearly when different data from different sequencing studies are analyzed. Finally, this type of sequencing analysis is challenging to implement in larger cohorts; thus, existing findings should be applied with caution and confirmed in clinical trials. Moreover, the individual differences among patients and different platforms applied in distinct trials limit the reliability of the results described above.

Multomics integrates high-throughput biomolecular data related to multiple factors, including the genome, transcriptome, proteome, interactome, epigenome and metabolism, among which the transcriptome is central. The multomics data promote the interrogation of complex interactions and connections in tumors at different states and with different phenotypes and also provides additional nuanced data on the dynamic progression of tumor initiation, progression, growth, immune evasion, metastasis, relapse and therapy resistance. The integration of multiomics methods improves the technical per-cell reliability and sensitivity, which results in superior accuracy, robustness, compatibility and expandability and even improves the preamplification procedure. Overall, these data contribute to establishing a complex computational framework, which enables the de novo discovery of both continuous and discrete expression patterns from single-cell sequencing data.

In conclusion, the integration of sequencing techniques can generate more complex, high-throughput information, including genomic, epigenomic, transcriptomic, proteomic, spatial and temporal data, necessitating the development of powerful and precise models or algorithms to provide new strategies for diagnosis, classification, targeted treatment and prognosis prediction. Notably, the accuracy and sensitivity of emerging technologies and computational analyses must be improved, and the costs should become more affordable in the near future.

Abbreviations

SCS: Single-cell sequencing; snRNA-seq: Single-nucleus RNA sequencing; ScSeq: Single-cell genomes with combinatorial indexing; RT: Reverse transcription; SPLIT-seq: Split-pool ligation-based transcriptome sequencing; FACS: Fluorescence-activated cell sorting; MARS-seq: Massively parallel single-cell RNA sequencing; inDrop: Indexing drop RNA sequencing; ScATAC-seq: Single-cell transposase-accessible chromatin using sequencing; CoBATCh: Combinatorial barcoding and targeted chromatin release; PAT: Trnsposase to protein A; CITE-seq: Cellular indexing of transcriptomes and epitopes by sequencing; TSO: Template switch oligo; IGS: In situ sequencing; CyTOF: Mass cytometry by time of flight; IMC: Imaging mass cytometry; LC–MS: Liquid chromatography–mass spectrometry; SCoPE-MS: Single-cell proteomics by mass spectrometry; t-SNE: T-distributed Stochastic Neighbor Embedding; PCA: Principal component analysis; CCA: Canonical correlation analysis; CNV: Copy number variation; DEG: Differently expressed gene; CAF: Cancer-associated fibroblast; GA: Gastric adenocarcinoma; LCM: Laser-capture microdissection; LINNAEUS: Lineage tracing by nuclelease-activated editing of ubiquitous sequences; TCR: T cell receptor; ScRNA-seq: Single-cell RNA sequencing; SNV: Single-nucleotide variation; CNV: Copy number variation; Sv: Structural variation; CTC: Circulating tumor cell; CSC: Cancer stem cell; TME: Tumor microenvironment; TGF-β1: Transforming growth factor β1; PDIA3: Protein disulfide isomerase family A member 3; PDAC: Pancreatic ductal adenocarcinoma; HCC: Hepatocellular carcinoma; ESCC: Esophageal squamous cell carcinoma; CA19: Cancer-associated fibroblast; TIL: Tumor-infiltrating lymphocyte; MSI: Microsatellite instability; MSS: Microsatellite stability; PD-1: Programmed death 1; CTLA-4: Cytotoxic T-lymphocyte-associated protein 4; DC: Dendritic cell; cDC: Conventional type 1 dendritic cell; Treg: Regulatory T cell; MIAT: Myocardial infarction associated transcript; CRISP-seq: ScRNA-seq on cluster regulatory interspaced short palindromic repeats–pooled screens; TAM: Tumor-associ-
and transcriptome sequencing; DR-Seq: DNA-mRNA sequencing; T-ATAC-seq: Transcript-indexed ATAC-seq; CORTAD-seq: Concurrent sequencing of the transcriptome and targeted genomic regions; scDam&T-seq: Single-cell DNA adenine methyltransferase identification with messenger RNA sequencing.

Acknowledgements
We thank American Journal Experts (AJE) for their assistance with language editing.

Authors’ contributions
YLL and TR collected the related papers and wrote the manuscript. JX, WW, BZ and JL participated in the design of the review, and SS and XJY initiated the study and revised and finalized the manuscript. All authors read and approved the final manuscript.

Funding
This study was funded by the National Natural Science Foundation of China (No 81802352, 81772555 and 81902428), the National Science Foundation for Distinguished Young Scholars of China (No. 81625016), the Shanghai Sailing Program (No. 19YF1409400 and 20YF1409000), the Shanghai Rising-Star Program (No. 20Q1402100), the Shanghai Anticancer Association Young Eagle Program (No. SACA-CY19A06), the Clinical and Scientific Innovation Project of Shanghai Hospital Development Center (No. SHDC12018109 and SHDC12019109), the Scientific Innovation Project of Shanghai Education Committee (No. 2019-01-07-00-07-E00057) and the Fudan University Shanghai Medical College Qing Feng Scholar Project (No. QF2110).

Availability of data and materials
Not applicable; all information in this review can be found in the reference list.

Declarations

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, No. 270 Dong‘An Road, Shanghai 200032, China. 2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. 3 Shanghai Pancreatic Cancer Institute, No. 270 Dong‘An Road, Shanghai 200032, China. 4 Pancreatic Cancer Institute, Fudan University, Shanghai, China.

Received: 17 April 2021 Accepted: 3 June 2021 Published online: 09 June 2021

References
1. Tang F, Barbacioru C, Wang Y, Nordman E, Lee C, Xu N, et al. mRNA-Seq whole-transcriptome analysis of a single cell. Nat Methods. 2009;6(5):377–82.
2. Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, et al. Tumour evolution inferred by single-cell sequencing. Nature. 2011;472(7341):90–4.
3. Paolillo C, Lordin E, Fortina P. Single-cell genomics. Clin Chem. 2019;65(8):972–85.
4. Zafar H, Wang Y, Nakhleh L, Navin N, Chen K. Monovar: single-nucleotide variant detection in single cells. Nat Methods. 2016;13(6):505–7.
5. Tirosi I, Venteicher AS, Hebert C, Escalante LE, Patel AP, Yizhak K, et al. Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma. Nature. 2016;539(7628):309–13.
6. Venteicher AS, Tirosi L, Hebert C, Yizhak K, Nefef C, Filbin MG, et al. Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-Seq. Science. 2017;355(6332):eaar8478.
7. Lake BB, Ai R, Kaestel GE, Salathia NS, Yung YC, Liu R, et al. Neuronal subtypes and diversity revealed by single-nucleus RNA sequencing of the human brain. Science. 2016;352(6293):1586–90.
8. Rosenberg AB, Roco CM, Muscat RA, Kucshin A, Sample P, Yao Z, et al. Single-cell profiling of the developing mouse brain and spinal cord with split-pool barcoding. Science. 2018;360(6385):176–82.
9. van Galen P, Hovestadt V, Wadsworth Li MH, Hughes TK, Griffin GK, Battaglia S, et al. Single-cell RNA-Seq reveals AML hierarchies relevant to disease progression and immunity. Cell. 2019;176(6):1265–81.
10. Zilioni R, Engblom C, Pfirsich C, Savoia V, Zemomm D, Saatkogliu HD, et al. Single-cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species. Immunity. 2019;50(5):1317–34.
11. Baslan T, Hicks J. Unravelling biology and shifting paradigms in cancer with single-cell sequencing. Nat Rev Cancer. 2017;17(9):557–69.
12. Zang L, Li Z, Skrzyczynska KM, Fang Q, Zhang W, O’Brien SA, et al. Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer. Cell. 2020;181(2):442–59.
13. Kolodziejczyk AA, Kim JK, Svensson V, Marioni JC, Teichmann SA. The technology and biology of single-cell RNA sequencing. Mol Cell. 2015;58(4):610–20.
14. O’Flanagan CH, Campbell KR, Zhang AW, Kabeer F, Lim JLP, Biele J, et al. Dissociation of solid tumor tissues with cold active protease for single-cell RNA-seq minimizes conserved collagenase-associated stress responses. Genome Biol. 2019;20(1):210.
15. Zhang X, Li T, Liu F, Chen Y, Yao J, Li Z, et al. Comparative analysis of droplet-based ultra-high-throughput single-cell RNA-Seq systems. Mol Cell. 2019;73(1):130–42.
16. Ding J, Adiconis X, Simmons SK, Kowalczyk MS, Hesson CC, Marjanovic ND, et al. Systematic comparison of single-cell and single-nucleus RNA-sequencing methods. Nat Biotechnol. 2020;38(6):737–46.
17. Vetrak SA, Torkenczy KA, Rosenkrantz JL, Fields AJ, Christiansen L, Wong MH, et al. Sequencing thousands of single-cell genomes with combinatorial indexing. Nat Methods. 2017;14(3):302–8.
18. Han X, Wang R, Zhou Y, Fei L, Sun H, Lai S, et al. Mapping the mouse cell atlas by Microwell-Seq. Cell. 2018;172(5):1091–107.
19. Ziegenhain C, Viertl B, Parekh S, Reinius B, Guillaumet-Adkins A, Smets M, et al. Comparative analysis of single-cell RNA sequencing methods. Mol Cell. 2017;65(4):631–43.
20. Jeyaparakash JD, Samuel S, Ruhe J. A facile photochemical surface modification technique for the generation of microstructured fluorinated surfaces. Langmuir. 2004;20(23):10080–5.
21. Singh S, Wang L, Schaff DL, Sutcliffe MD, Koeppel AF, Kim J, et al. In situ 10-cell RNA sequencing in tissue and tumor biopsy samples. Sci Rep. 2019;9(1):4836.
22. Woo J, Winterhoff BJ, Stai TK, Alleris C, Wang J, et al. De novo prediction of cell-type complexity in single-cell RNA-seq and tumor microenvironments. Life Sci Alliance. 2019. https://doi.org/10.26508/lisa.2019000443.
23. Levitin HM, Yuan J, Cheng YL, Ruiz FJ, Bush EC, Bruce JN, et al. De novo gene signature identification from single-cell RNA-seq with hierarchical Poisson factorization. Mol Syst Biol. 2019. https://doi.org/10.15252/msb.20188557.
24. Xie P, Gao M, Wang C, Zhang J, Noel P, Yang C, et al. SuperCT: a supervised-learning framework for enhanced characterization of single-cell transcriptomic profiles. Nucleic Acids Res. 2019. https://doi.org/10.1093/nar/gkz116.
25. Zhang L, Tao S, Zhang L, Diao LT, Huang X, Huang S, et al. RNA sequencing: new technologies and applications in cancer research. J Hematol Oncol. 2020;13(1):166.
26. Ramskold D, Luo S, Wang YC, Li R, Deng Q, Faridani OR, et al. Full-length mRNA-Seq from single-cell levels of RNA and individual circulating tumor cells. Nat Biotechnol. 2012;30(8):777–82.
27. Picelli S, Bjorklund AK, Faridani OR, Sagasser S, Winberg G, Sandberg R. Smart-seq2 for sensitive full-length transcriptome profiling in single cells. Nat Methods. 2013;10(1):1096–8.
28. Song Y, Milon B, Ott S, Zhao X, Sadzewicz L, Shetty A, et al. A comparative analysis of library prep approaches for sequencing low input transliterator samples. BMC Genom. 2018;19(1):1696.

29. Bell OH, Copeland DA, Ward A, Nicholson LB, Lange CAK, Chu CJ, et al. Single cell mRNA-Seq reveals normalisation of the retinal microglial transcriptome following acute inflammation. Front Immunol. 2019;10:3033.

30. Bjorklund AK, Forkel M, Picelli S, Konya V, Theorell J, Friberg D, et al. The heterogeneity of human CD127(+/-) innate lymphoid cells revealed by single-cell RNA sequencing. Nat Immunol. 2016;17(4):451–60.

32. Wang X, He Y, Zhang Q, Ren X, Zhang Z. Direct comparative analyses of 10X genomics chromium and smart-seq2. Genom Proteomics Bioinformatics. 2020;8:100105.

33. Zhang Q, He Y, Luo N, Patel SJ, Han Y, Gao R, et al. Landscape and dynamics of single immune cells in hepatocellular carcinoma. Cell. 2019;179(4):829–45.

34. Coons AH, Creech HJ, Jones RN. Immunological properties of an antibody containing a fluorescent group. Proc Soc Exp Biol Med. 1941;47(2):200–2.

35. Gall JI, Pardue ML. Formation and detection of RNA-DNA hybrid molecules in cytological preparations. Proc Natl Acad Sci USA. 1969. https://doi.org/10.1073/pnas.66.3.378.

36. Geng S, Wang J, Zhang X, Zhang JJ, Wu F, Pang Y, et al. Single-cell RNA sequencing reveals chemokine self-feeding of myeloma cells promotes extramedullary metastasis. FEMS Lett. 2020;594(3):452–65.

37. Jackson HW, Fischer JR, Zancotti VR, Altb HR, Mecheza R, Soysal SD, et al. The single-cell pathology landscape of breast cancer. Nature. 2020;578(7796):615–20.

38. McCarthy DJ, Rostom R, Huang Y, Kunz DJ, Danekc P, Bonder MJ, et al. Cardelino: computational integration of somatic clonal substructure and single-cell transcriptions. Nat Methods. 2020;17(4):414–21.

39. Moncada R, Barkley D, Wagner F, Chodin M, Devlin JC, Baron M, et al. Integrating microarray-based spatial transcriptomics and single-cell RNA-seq reveals tissue architecture in pancreatic ductal adenocarcinoma. Nat Biotechnol. 2020;38(3):333–42.

40. Stahl P, Salmen F, Vckovic S, Lundmark A, Navaro JF, Magnusson J, et al. Visualization and analysis of gene expression in tissue sections by spatial transcriptomics. Science. 2016;353(6294):78–82.

41. Spanjaard B, Hu B, Miett C, Olivers-Chauvet P, Januha S, Ninov N, et al. Simultaneous lineage tracing and cell-type identification using CRISPR-Cas9-induced genetic scars. Nat Biotechnol. 2018;36(5):669–73.

42. Quinn JJ, Jones AK, Okimoto RA, Nano S, Chan MM, Yossef N, et al. Single-cell lineages reveal the rates, routes, and drivers of metastasis in cancer xenografts. Science. 2021. https://doi.org/10.1126/science.abc1944.

43. Velten L, Story BA, Hernandez-Malmeire P, Raffel S, Leisong DR, Millbank J, et al. Identification of leukemic and pre-leukemic stem cells by clonal tracking from single-cell transcriptomics. Nat Commun. 2021;12(1):1366.

44. Grindberg RV, Yee-Greenbaum JL, McConnell MJ, Novotny M, O'Shaughnessy AL, Lambert GM, et al. RNA-sequencing from single nuclei. Proc Natl Acad Sci USA. 2013;110(49):19802–7.

45. Habib N, Liu Y, Heidenreich M, Swiech L, Avraham-David I, Lombetta JI, et al. Div-Seq: single-nucleus RNA-Seq reveals dynamics of rare adult newborn neurons. Science. 2016;353(6292):925–8.

46. Habib N, Avraham-David I, Basu A, Burks T, Shekhar K, Hofree M, et al. Massively parallel single-nucleus RNA-seq with DroNc-seq. Nat Methods. 2017. https://doi.org/10.1038/nmeth.4407.

47. Spyker M, Porter CM, Ashenberg O, Waldman J, Droklyshuksy E, Wakin L, et al. A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors. Nat Med. 2020;26(5):792–802.

48. Rodriguez-Meira A, Buck G, Clark SA, Povinelli BJ, Alcolea V, Louka E, et al. Unravelling intratumoral heterogeneity through high-sensitivity single-cell mutational analysis and parallel RNA sequencing. Mol Cell. 2019;73(6):1292–305.

49. McCarthy DJ, Rostom R, Huang Y, Kunz DJ, Danekc P, Bonder MJ, et al. Transcript-indexed ATAC-seq for precision immune profiling. Nat Med. 2018;24(5):580–90.

50. Barosov M, Kabbe M, Castello-Branco G. Single-cell CUT&Tag profiles histone modifications and transcription factors in complex tissues. Nat Biotechnol. 2021. https://doi.org/10.1038/s41587-021-00869-9.

51. Payne AC, Chang ZD, Regnato PL, Mangiameli SM, Murray EM, Yao CC, et al. In situ genome sequencing resolves DNA sequence and structure in intact biological samples. 2021. https://doi.org/10.1126/science.aay5446.

52. Tan L, Ma W, Hu W, Zheng Y, Xing D, Chen R, et al. Changes in genome architecture and transcriptional dynamics progress independently of sensory experience during post-natal brain development. Cell. 2021;184(3):741–58.

53. Veenastra J, Dimitriou P, Yao Y, Zhou L, Ozog D, MI QS. Research techniques made simple: use of imaging mass cytometry for dermatological research and clinical applications. J Invest Dermatol. 2021;114(4):705–12.

54. Cheung TK, Lee KY, Bayer FP, McCoy A, Kuster B, Rose CM. Defining the carrier proteome limit for single-cell proteomics. Nat Methods. 2019;18(1):76–83.

55. Markedimidaki CM, Rang Ef, Roojiers K, de Vries SS, Chialastria A, de Luca KL, et al. Simultaneous quantification of protein-DNA interactions and transcriptions in single cells with scDamTaq profiles. Nat Protoc. 2020;15(8):1922–53.

56. Song SL, Li H, Tai JA, Courtois ET, Poh HM, Lau DP, et al. Concurrent single-cell RNA and targeted DNA sequencing on an automated platform for comereament of genome and transcriptomic signatures. Clin Chem. 2019;65(2):272–81.

57. Campbell KR, Steif A, Laks E, Zahn H, Lai D, McPherson A, et al. Clonealign: statistical integration of independent single-cell RNA and DNA sequencing data from human cancers. Genome Biol. 2019;20(1):54.

58. Rios AC, Capaldo BD, Villamil F, Pal B, van Ievenk D, Dawson CA, et al. Intracellular plasticity in mammmary tumors revealed through large-scale single-cell resolution 3D imaging. Cancer Cell. 2019;35(4):618–32.

59. Katzenellenbogen Y, Sheban F, Yalin A, Youl V, Svetchlinny D, Jaita DA, et al. Coupled scRNA-Seq and intracellular protein activity reveal an immunosuppressive role of TREM2 in cancer. Cell. 2020;182(4):872–85.

60. Okonkwochik K, Pfeifer SM, Kutscher LM. Probing medulloblastoma initiation at the single-cell level. Trends Cancer. 2019;5(12):759–61.

61. Kim N, Kim HK, Lee K, Hong Y, Cho JH, Choi JW, et al. Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma. Nat Commun. 2020;11(1):2285.

62. Wu J, Xiao Y, Sun J, Sun H, Chen H, Zhu Y, et al. A single-cell survey of cellular hierarchy in acute myeloid leukemia. J Hematol Oncol. 2020;13(1):128.

63. Rozenblatt-Rosen O, Regev A, Oberdoerffer P, Nawy T, Hupaloowska A, Rood J, et al. The human tumor atlas network: charting tumor types and novel cell states revealed in fibrosis. J Am Soc Nephrol. 2019;30(1):23–32.
transitions across space and time at single-cell resolution. Cell. 2020;181(2):236–49.

71. Liudahl SM, Betts CB, Sivagnanam S, Morales-Dyarrive V, da Silva A, Yuan C, et al. Leukocyte heterogeneity in pancreatic ductal adenocarcinoma: phenotypic and spatial features associated with clinical outcome. Cancer Discov. 2021. https://doi.org/10.1158/2159-8290.CD-20-0841.

72. Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531(7592):47–52.

73. Collisson EA, Sadanandom A, Olson P, Gibb WI, Truitt M, Gu S, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011;17(4):500–3.

74. Moffitt RA, Marayati R, Rate E, Volmar KE, Loeza SGH, Hoadley KA, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet. 2015;47(10):1168–70.

75. Cancer Genome Atlas Research Network. Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell. 2013;23(2):185–203.

76. Karasinska JM, Topham JT, Kalloger SE, Jang GH, Denroche RE, Culibrk L, et al. Single-cell sequencing and its application in metastasis. Cell. 2019;179(3):673–88.e18.

77. Praktiknjo SD, Obermayer B, Zhu Q, Fang L, Liu H, Quinn H, et al. Tracing tumor evolution in sarcoma reveals clonal origin of advanced metastasis. Cell Rep. 2019;28(11):2887–50.

78. Yang D, Yang Q, Lv X, Huang W, Zhou Z, et al. Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma. Nat Commun. 2020;11(1):6322.

79. Vladoiu MC, El-Hamamy I, Donovan LK, Farrow HO, Holgado BL, Sundaravadanam Y, et al. Childhood cerebellar tumours mirror conserved fetal transcriptional programs. Nature. 2019;572(7767):67–73.

80. Tang YJ, Huang J, Tshushma H, Ban GJ, Zhang H, Oristian KV, et al. Tracing tumor evolution in sarcoma reveals clonal origin of advanced metastasis. Cell Rep. 2019;28(11):2887–50.

81. Kyrotchiros ID, Roukos DH. Comprehensive intra-individual genomic and transcriptional heterogeneity: evidence-based Colorectal Cancer Precision Medicine. Cancer Treat Rev. 2019;80:101894.

82. Davis RT, Blake K, Ma D, Gabra MBI, Hernandez GA, Phung AT, et al. Transcriptional diversity and bioenergetic shift in human breast cancer metastasis revealed by single-cell RNA sequencing. Nat Cell Biol. 2020;22(3):310–20.

83. Tieng FYF, Baharudin R, Abu N, Mohd Yusof RI, Lee LH, Ab Mutalib NS. Single-cell transcriptome in colorectal cancer-current updates on its application in metastasis, chemoresistance and the roles of circulating tumor cells. Front Pharmacol. 2020;11:135.

84. Teo YV, Rattanavirotkul N, Olova N, Salzano A, Quintanilla A, Tarrats A, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet. 2015;47(10):1168–70.

85. Zhang M, Hu S, Min M, Ni Y, Lu Z, Sun X, et al. Dissecting transcriptional programs of primary gastric adenocarcinoma by single cell RNA sequencing. Gut. 2020. https://doi.org/10.1136/gutjnl-2019-320368.

86. Peng J, Sun BF, Chen CY, Zhou JY, Chen YS, Chen H, et al. Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma. Cell Res. 2019;29(9):725–38.

87. Chen YC, Jung S, Zhang Z, Wicha MS, Yoon E. Co-culture of functionally differentiated human colorectal cancer cells enables contamination-free high-throughput single-cell RNA-sequencing for circulating tumor cells. Nat Commun. 2019;10(1):2163.

88. Liu Y, Ye G, Huang L, Zhang C, Sheng Y, Wu B, et al. Altered gene expression along the glycolysis-cholesterol synthesis axis is associated with outcome in pancreatic cancer. Clin Cancer Res. 2020;26(2):135–46.

89. Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG, et al. A restricted neurodevelopmental hierarchy. Nat Commun. 2020;11(1):3406.

90. Jin L, Vu T, Yuan G, Datta PK. STRAP promotes stemness of human colorectal cancer cells. Genes Cancer. 2020;11(1):6322.

91. Davis RT, Blake K, Ma D, Gabra MBI, Hernandez GA, Phung AT, et al. Transcriptional diversity and bioenergetic shift in human breast cancer metastasis revealed by single-cell RNA sequencing. Nat Cell Biol. 2020;22(3):310–20.

92. Tyagi S, Laemmli UK, Tan PH, Viale A, Viale G. A restricted neurodevelopmental hierarchy. Nat Commun. 2020;11(1):3406.
113. Banno A, Garcia DA, van Baarzel ED, Metz PJ, Fisch K, Widjaja CE, et al. Downregulation of 26S proteasome catalytic activity promotes epithelial-mesenchymal transition. Oncotarget. 2016;7(16):21527–41.

114. Ho DW, Tsui YM, Sze KM, Chan LK, Cheung TT, Lee E, et al. Single-cell transcriptomics reveals the landscape of intra-tumoral heterogeneity and stemness-related subpopulations in liver cancer. Cancer Lett. 2019;459:176–85.

115. Meyer M, Reimand J, Lan X, Head R, Zhu C, Kushida M, et al. Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity. Proc Natl Acad Sci USA. 2015;112(3):851–6.

116. Olive KP, Jacobetz MA, Davidson CJ, McIntryre D, Hones D, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324(5933):1457–61.

117. Provenzano PP, Cuevaes C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21(3):418–29.

118. Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut. 2013;62(1):112–20.

119. Laklai H, Miroshnikova YA, Pickup MW, Collisson EA, Kim GE, Barrett AS, et al. Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Nat Med. 2016;22(5):497–505.

120. Olivaso E, Mayers JR, Gourand V, Torrence ME, Gicquel T, Borge L, et al. Collagen-derived proline promotes pancreatic ductal adenocarcinoma cell survival under nutrient limited conditions. Nat Commun. 2017;8:16031.

121. Rice AJ, Cortez E, Lachowski D, Cheung BC, Karim SA, Morton JP, et al. Matrix stiffness induces epithelial-mesenchymal transition and promotes chemoresistance in pancreatic cancer cells. Oncogenesis. 2017. https://doi.org/10.1038/oncsis.2017.54.

122. Peran I, Dhakshanamurthy S, McCoy MD, Mavropoulos A, Allo B, Sebastian A, et al. Cadherin 11 promotes immunosuppression and extracellular matrix deposition to support growth of pancreatic tumors and resistance to gemcitabine in mice. Gastroenterology. 2021. https://doi.org/10.1053/j.gastro.2020.11.044.

123. Erez N, Truitt M, Olson P, Hanahan D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-κB-dependent manner. Cancer Cell. 2010;17(2):135–47.

124. Tjomsland V, Niklasson L, Sandström P, Borch K, Druid K, Bratthäll C, et al. Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Nat Med. 2016;22(5):497–505.

125. Peel I, Jones JO, Kraman M, Wells RJB, Deonarine A, Chan DS, et al. Tartrate-sensitive ATPase 5A/6A promotes chemoresistance in pancreatic cancer cells. Oncogenesis. 2017. https://doi.org/10.1038/oncsis.2017.54.

126. Zhang Y, Yan W, Collins MA, Bednar F, Rakshit S, Zetter BR, et al. Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance. Cancer Res. 2013;73(20):6359–74.

127. Sherman MH, Yu RT, Engle DD, Ding N, Atkins AR, Tiriac H, et al. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell. 2014;159(1):80–93.

128. Öhlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med. 2017;214(3):579–96.

129. McAndrews KM, Chen Y, Kalluri R. Stromal cells exhibit prevalent genetic aberrations in colorectal cancer. Cancer Cell. 2020;38(6):774–5.

130. Massalha H, Bahar Halpern K, Abu-Gazala S, Jana T, Massasa EE, Moor RM, et al. Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Nat Med. 2013. https://doi.org/10.1038/ncomms12012.

131. Zhang H, Yan W, Collins MA, Bednar F, Rakshit S, Zetter BR, et al. Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance. Cancer Res. 2013;73(20):6359–74.

132. Sherman MH, Yu RT, Engle DD, Ding N, Atkins AR, Tiriac H, et al. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell. 2014;159(1):80–93.

133. Öhlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med. 2017;214(3):579–96.

134. McAndrews KM, Chen Y, Kalluri R. Stromal cells exhibit prevalent genetic aberrations in colorectal cancer. Cancer Cell. 2020;38(6):774–5.

135. Massalha H, Bahar Halpern K, Abu-Gazala S, Jana T, Massasa EE, Moor RM, et al. Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Nat Med. 2013. https://doi.org/10.1038/ncomms12012.

136. Prieto J, Melero I, Sangro B. Immuno-oncology landscape and immuno-therapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2015;12(12):681–700.

137. Brooks ED, Chang CY. Time to abandon single-site irradiation for inducing abscopal effects. Nat Rev Clin Oncol. 2019;16(2):123–35.

138. Hu J, Chen Z, Bao L, Zhao J, Hou Y, Liu L, et al. Single-cell transcriptome analysis reveals intratumoral heterogeneity in ccRCC, which results in different clinical outcomes. Mol Ther. 2020;28(7):1658–72.
155. Magen A, Nie J, Ciucci T, Tamoutounour S, Zhao Y, Mehta M, et al. Single-cell profiling defines transcriptomic signatures specific to tumor-reactive versus virus-responsive CD4+ T cells. Cell Rep. 2019;29(10):3019–32.

156. Kato Y, Tabata K, Kimura T, Yachie-Kinosita A, Ozawa Y, Yamada K, et al. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS ONE. 2019;14(2):e0212513.

157. Katsuta E, Qi QY, Peng X, Hochwald SN, Yan L, Takabe K. Pancreatic adenocarcinomas with mature blood vessels have better overall survival. Sci Rep. 2019;9(1):1310.

158. Goswami S, Walle T, Cornish AE, Basu S, Anandhan S, Fernandez J, et al. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nat Med. 2020;26(1):39–46.

159. Suzuki A, Matsushima K, Makinoshima H, Sugano S, Kohno T, Tsuchihara K, et al. Single-cell analysis of lung adenocarcinoma cell lines reveals diverse expression patterns of individual cells invoked by a molecular target drug treatment. Genome Biol. 2015;16:666.

160. Su X, Long Q, Bo J, Shi Y, Zhao LN, Lin Y, et al. Mutational and transcriptomic landscapes of a rare human prostate basal cell carcinoma. Prostate. 2020;80(6):508–17.

161. Sa JK, Cho SW, Zhao J, Lee Y, Zhang J, Kong DS, et al. Hypermutagenesis in untreated adult gliomas due to inherited mismatch mutations. Int J Cancer. 2019;144(3):3023–30.

162. Jerby-Aronn L, Shah P, Cuosco MS, Rodman C, Su MQ, Melms JC, et al. A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade. Cell. 2018;175(4):984–97.

163. Hong SP, Chan TE, Lombardo Y, Corleone G, Rotmensz N, Bravaccini S, et al. Single-cell transcriptomics reveals multi-step adaptations to endocrine therapy. Nat Commun. 2019;10(1):3840.

164. Gurjao C, Liu D, Hofree M, AlDubayan SH, Wakiro I, Su MJ, et al. Intrinsic resistance to immune checkpoint blockade in a mismatch repair-deficient colorectal cancer. Cancer Immunol Res. 2019;7(1):230–6.

165. Rendeiro AF, Krausgruber T, Fortelny N, Zhao F, Penz T, Farlik M, et al. Ibrutinib inhibits BCR and NF-kappaB signaling and reduces tumor burden in a lymphoma mouse model. Blood. 2017;130(26):e2134–42.

166. Herman SE, Mustafa RZ, Gyamfi JA, Pittaluga S, Chang S, Chang B, et al. Ibrutinib and palliative radiotherapy on clinical outcomes in patients with stage IV non-small cell lung cancer (NSCLC). Int J Radiat Oncol. 2020. https://doi.org/10.1016/j.radonc.2020.07.2218.

167. Yang L, Zhang X, Hou Q, Huang M, Zhang H, Jiang Z, et al. Single-cell RNA-seq of esophageal squamous cell carcinoma cell line with fractionated irradiation reveals radiosensitive gene expression patterns. BMC Genom. 2019;20(1):611.

168. Srivatsan SR, McFalone-Figueroa JL, Ramani V, Saunders L, Cao J, Packer I, et al. Massively multiplexed chemical transcriptomics at single-cell resolution. Science. 2020;367(6473):45–51.

169. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010;467(7319):1144–7.

170. Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). The Lancet. 2017;390(10103):1564–63.

171. Nguyen DX, Bos PD, Massagué J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009;9(4):274–84.

172. Vasudev NS, Reynolds AR. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis. 2014;17(3):471–94.

173. Daneshmanesh AH, Hojat-Farsangi M, Ghaderi A, Moshref A, Hansson L, Schultz J, et al. A receptor tyrosine kinase ROR1 inhibitor (RANO439834) induced significant apoptosis of pancreatic cells which was enhanced by etolizumab and ibritinib. PLoS ONE. 2018;13(6):e0198308.

174. Chang Y, Li G, Zhai Y, Huang L, Feng Y, Wang D, et al. Redox regulator GLRX is associated with tumor immunity in glioma. Front Immunol. 2020;11:580934.

175. Tanaka N, Katayama S, Reddy A, Nishimura K, Niwa N, Hongo H, et al. Single-cell RNA-seq analysis reveals the platinum resistant gene COX7B and the surrogate marker CD63. Cancer Med. 2018;7(12):6193–204.

176. L’Esperance S, Popa I, Bachvarova M, Plante M, Patten N, Wu L, et al. Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors. Int J Oncol. 2006;29(1):5–24.

177. Hannemann J, Oosterkamp HM, Bosch CA, Velds A, Wessels LF, Loo C, et al. Changes in gene expression associated with response to neoadjuvant chemotherapy: molecular signatures of chemoresistant tumors. Int J Oncol. 2006;29(1):5–24.
197. Wang Q, Xiong H, Ai S, Yu X, Liu Y, Zhang J, et al. CoBATCH for high-throughput single-cell epigenomic profiling. Mol Cell. 2019;76(1):206–16.

198. Buenrostro JD, Wu B, Litzenburger UM, Ruff D, Gonzales ML, Snyder MP, et al. Single-cell chromatin accessibility reveals principles of regulatory variation. Nature. 2015;523(7561):486–90.

199. Stoeckius M, Hafemeister C, Stephenson W, Huber LO, Chatterjee SK, et al. Simultaneous epitope and transcriptome measurement in single cells. Nat Methods. 2017;14(9):865–8.

200. Peterson VM, Zhang K, Kumar N, Wong J, Li L, Wilson DC, et al. Multiplexed quantification of proteins and transcripts in single cells. Nat Biotechnol. 2017;35(10):936–9.

201. Sinjab A, Han G, Vaillant F, Capaldo BD, Joyce R, Song X, et al. A single-cell RNA expression atlas of normal, preneoplastic and tumorigenic states in the human breast. Embo J. 2021. https://doi.org/10.15252/embj.2020107333.

202. Wagner J, Rapsomaniki MA, Chevrier S, Anzeneder T, Langwieder C, et al. Resolving the spatial and cellular architecture of lung adenocarcinoma by multiregion single-cell sequencing. Cancer Discov. 2021. https://doi.org/10.1158/2159-8290.CD-20-1285.

203. Mathewson ND, Allenberg T, Sderbergs MA, et al. Single-cell chromatin accessibility reveals principles of regulatory variation. Nature. 2021;593(7857):495–503.

204. Zheng Y, Han Y, Han L, Zhou B, et al. Single-cell RNA-seq profiling identifies combined AXL and JAK1 as a novel therapeutic strategy for lung cancer. Cancer Res. 2021;81(14):3639–45.

205. Dong Y, Wang Z, Shi Q, Liquid biopsy based single-cell transcriptome profiling characterizes heterogeneity of disseminated tumor cells from lung adenocarcinoma. Proteomics. 2020;20(13):e1900224.

206. Alshetaiwi H, Pervolarakis N, Nguyen QH, Kessenbrock K. Single-cell transcriptome analysis workflow for splenic myeloid-derived suppressor cells in mouse breast cancer models. Methods Mol Biol. 2020;21236:177–87.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.